<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34191081</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>269</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>885</StartPage><EndPage>896</EndPage><MedlinePgn>885-896</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-021-10670-y</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate the efficacy and safety of perampanel in patients with sporadic amyotrophic lateral sclerosis (SALS).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This randomized, double-blind, placebo-controlled, multicenter, phase 2 clinical study was conducted at 12 sites. Patients with probable or definite ALS as defined by revised El Escorial criteria were enrolled. Sixty-six patients were randomly assigned (1:1:1) to receive placebo, 4&#xa0;mg perampanel, or 8&#xa0;mg perampanel daily for 48&#xa0;weeks. Adverse events (AEs) were recorded throughout the trial period. The primary efficacy outcome was the change in Amyotrophic Lateral Sclerosis Rating Scale-Revised (ALSFRS-R) score after 48&#xa0;weeks of treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One patient withdrew before starting the treatment. Of 65 patients included, 18 of 22 patients randomized to placebo (82%), 14 of 22 patients randomized to 4&#xa0;mg perampanel (64%), and 7 of 21 patients randomized to 8&#xa0;mg perampanel (33%) completed the trial. There was a significant difference in the change of ALSFRS-R scores [-&#xa0;8.4 (95% CI -&#xa0;13.9 to&#x2009;-&#x2009;2.9); p&#x2009;=&#x2009;0.015] between the placebo and the perampanel 8&#xa0;mg group, primarily due to worsening of the bulbar subscore in the perampanel 8&#xa0;mg group. Serious AEs were more frequent in the perampanel 8&#xa0;mg group than in the placebo group (p&#x2009;=&#x2009;0.0483).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Perampanel was associated with a significant decline in ALSFRS-R score and was linked to worsening of the bulbar subscore in the 8&#xa0;mg group.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aizawa</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5395-695X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Tokyo Medical University, Tokyo, Japan. haizawa@tokyo-med.ac.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kato</LastName><ForeName>Haruhisa</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oba</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biostatics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawahara</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Central Coordinating Unit, Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okubo</LastName><ForeName>Yoshihiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Tomoko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naito</LastName><ForeName>Makiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urushitani</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shiga University of Medical Science, Otsu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamaoka</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Clinical Medicine, Department of Neurology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamagoe</LastName><ForeName>Kiyotaka</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Clinical Medicine, Department of Neurology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Clinical Medicine, Department of Neurology, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanda</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atsuta</LastName><ForeName>Naoki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Yasushi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Kumamoto Saishun Medical Center, Kumamoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagai</LastName><ForeName>Makiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishiyama</LastName><ForeName>Kazutoshi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishiura</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toda</LastName><ForeName>Tatsushi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawata</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abe</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Okayama, Okayama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yabe</LastName><ForeName>Ichiro</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi-Iwata</LastName><ForeName>Ikuko</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Hidenao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Warita</LastName><ForeName>Hitoshi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tohoku University Hospital, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aoki</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tohoku University Hospital, Sendai, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sobue</LastName><ForeName>Gen</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizusawa</LastName><ForeName>Hidehiro</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>National Center of Neurology and Psychiatry, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuyama</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haga</LastName><ForeName>Tomohiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Central Coordinating Unit, Clinical Research Support Center, The University of Tokyo Hospital, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kwak</LastName><ForeName>Shin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokyo Medical University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CCT-B-2804</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009570">Nitriles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011728">Pyridones</NameOfSubstance></Chemical><Chemical><RegistryNumber>H821664NPK</RegistryNumber><NameOfSubstance UI="C551441">perampanel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009570" MajorTopicYN="N">Nitriles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011728" MajorTopicYN="N">Pyridones</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AMPA receptor</Keyword><Keyword MajorTopicYN="N">Efficacy</Keyword><Keyword MajorTopicYN="N">Perampanel</Keyword><Keyword MajorTopicYN="N">Safety</Keyword><Keyword MajorTopicYN="N">Sporadic amyotrophic lateral sclerosis</Keyword></KeywordList><CoiStatement>K.O. reports receiving honoraria from Takeda Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd, Eisai Co., Ltd, Chugai Pharmaceutical Co, Ltd., and Daiichi Sankyo Co., Ltd., outside the submitted work. M.K. reports receiving grants from AMED, Japan, during the conduct of the study; receiving grants from Mitsubishi Tanabe Pharma, grants from Sanofi, and consulting fees from Eisai, outside the submitted work. N.A. reports receiving grants from the Center for Clinical Trials, Japan Medical Association, during the conduct of the study. H.I. reports receiving speaker fees from Eisai, outside the submitted work. M.A. reports receiving research grants for Research on Nervous and Mental Disorders, Research on Rare and Intractable Diseases, Research on Psychiatric and Neurological Diseases and Mental Health from the Japanese Ministry of Health Labor and Welfare; Grants-in-Aid for Scientific Research, an Intramural Research Grant for Neurological Psychiatric Disorders from National Center of Neurology and Psychiatry (NCNP); Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT); and a grants of Practical Research Project for Rare/Intractable Diseases from the Japan Agency for Medical Research and Development (AMED); and funding for travel and speaker honoraria from Eisai Inc., Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Takeda Pharmaceutical Company Ltd, Sanofi K.K. Novartis Pharma K.K and Dainippon Sumitomo Pharma Co. Ltd. H.M. reports receiving grants from the Japan Agency for Medical Research and Development and grants from the Japanese Ministry of Health, Labor and Welfare, outside the submitted work. The other authors have nothing to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>30</Day><Hour>12</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34191081</ArticleId><ArticleId IdType="pmc">PMC8782807</ArticleId><ArticleId IdType="doi">10.1007/s00415-021-10670-y</ArticleId><ArticleId IdType="pii">10.1007/s00415-021-10670-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Jr, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:1602&#x2013;1671. doi: 10.1056/NEJMc1710379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1710379</ArticleId><ArticleId IdType="pubmed">29045202</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41:118&#x2013;130. doi: 10.1159/000351153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Boum&#xe9;diene F, Logroscino G, et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. 2017;46:57&#x2013;74. doi: 10.1093/ije/dyw061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyw061</ArticleId><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol. 2016;138:225&#x2013;238. doi: 10.1016/B978-0-12-802973-2.00013-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-802973-2.00013-6</ArticleId><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen HP, Van Broeckhoven C, van der Zee J. ALS genes in the genomic era and their implications for FTD. Trends Genet. 2018;34:404&#x2013;423. doi: 10.1016/j.tig.2018.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tig.2018.03.001</ArticleId><ArticleId IdType="pubmed">29605155</ArticleId></ArticleIdList></Reference><Reference><Citation>Chia R, Chi&#xf2; A, Traynor BJ. Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol. 2018;17:94&#x2013;102. doi: 10.1016/S1474-4422(17)30401-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30401-5</ArticleId><ArticleId IdType="pmc">PMC5901717</ArticleId><ArticleId IdType="pubmed">29154141</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey JH, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol. 2018;17:416&#x2013;422. doi: 10.1016/S1474-4422(18)30054-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group; Edaravone (MCI-186) ALS 19 Study Group Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss JH, Choi DW. Slow non-NMDA receptor mediated neurotoxicity and amyotrophic lateral sclerosis. Adv Neurol. 1991;56:311&#x2013;318.</Citation><ArticleIdList><ArticleId IdType="pubmed">1649543</ArticleId></ArticleIdList></Reference><Reference><Citation>Carriedo SG, Yin HZ, Weiss JH. Motor neurons are selectively vulnerable to AMPA/kainate receptor-mediated injury in vitro. J Neurosci. 1996;16:4069&#x2013;4079. doi: 10.1523/JNEUROSCI.16-13-04069.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.16-13-04069.1996</ArticleId><ArticleId IdType="pmc">PMC6578994</ArticleId><ArticleId IdType="pubmed">8753869</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Bosch L, Vandenberghe W, Klaassen H, Van Houtte E, Robberecht W. Ca(2+)-permeable AMPA receptors and selective vulnerability of motor neurons. J Neurol Sci. 2000;180:29&#x2013;34. doi: 10.1016/s0022-510x(00)00414-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(00)00414-7</ArticleId><ArticleId IdType="pubmed">11090861</ArticleId></ArticleIdList></Reference><Reference><Citation>Langan YM, Lucas R, Jewell H, et al. Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia. 2003;44:46&#x2013;53. doi: 10.1046/j.1528-1157.2003.128902.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1528-1157.2003.128902.x</ArticleId><ArticleId IdType="pubmed">12581229</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascuzzi RM, Shefner J, Chappell AS, et al. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:266&#x2013;271. doi: 10.3109/17482960903307805.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903307805</ArticleId><ArticleId IdType="pubmed">19961264</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;197:19&#x2013;24. doi: 10.1111/ane.12100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12100</ArticleId><ArticleId IdType="pmc">PMC4506647</ArticleId><ArticleId IdType="pubmed">23480152</ArticleId></ArticleIdList></Reference><Reference><Citation>Akamatsu M, Yamashita T, Hirose N, Teramoto S, Kwak S. The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci Rep. 2016;6:28649. doi: 10.1038/srep28649.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep28649</ArticleId><ArticleId IdType="pmc">PMC4923865</ArticleId><ArticleId IdType="pubmed">27350567</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideyama T, Yamashita T, Suzuki T, et al. Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2. J Neurosci. 2010;30:11917&#x2013;11925. doi: 10.1523/JNEUROSCI.2021-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2021-10.2010</ArticleId><ArticleId IdType="pmc">PMC6633551</ArticleId><ArticleId IdType="pubmed">20826656</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, Hideyama T, Hachiga K, et al. A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nat Commun. 2012;3:1307. doi: 10.1038/ncomms2303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2303</ArticleId><ArticleId IdType="pubmed">23250437</ArticleId></ArticleIdList></Reference><Reference><Citation>Melcher T, Maas S, Herb A, Sprengel R, Seeburg PH, Higuchi M. A mammalian RNA editing enzyme. Nature. 1996;379:460&#x2013;464. doi: 10.1038/379460a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/379460a0</ArticleId><ArticleId IdType="pubmed">8559253</ArticleId></ArticleIdList></Reference><Reference><Citation>Takuma H, Kwak S, Yoshizawa T, Kanazawa I. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol. 1999;46:806&#x2013;815. doi: 10.1002/1531-8249(199912)46:6&lt;806::aid-ana2&gt;3.0.co;2-s.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1531-8249(199912)46:6&lt;806::aid-ana2&gt;3.0.co;2-s</ArticleId><ArticleId IdType="pubmed">10589532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y, Ito K, Sun H, Aizawa H, Kanazawa I, Kwak S. Glutamate receptors: RNA editing and death of motor neurons. Nature. 2004;427:801. doi: 10.1038/427801a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/427801a</ArticleId><ArticleId IdType="pubmed">14985749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideyama T, Yamashita T, Aizawa H, et al. Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol Dis. 2012;45:1121&#x2013;1128. doi: 10.1016/j.nbd.2011.12.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.12.033</ArticleId><ArticleId IdType="pubmed">22226999</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, et al. WFN Research Group On ALS/MND. A revision of the El Escorial criteria&#x2014;2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:291&#x2013;292. doi: 10.3109/21678421.2015.1049183.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1049183</ArticleId><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>Medical Research Council . Aids to the investigation of the peripheral nervous system. London: Her Majesty's Stationery Office; 1976.</Citation></Reference><Reference><Citation>Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266&#x2013;1277. doi: 10.1176/appi.ajp.2011.10111704.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2011.10111704</ArticleId><ArticleId IdType="pmc">PMC3893686</ArticleId><ArticleId IdType="pubmed">22193671</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et al. The Writing Group Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;ckl S, Koch A, Lasch F. Empirical evaluation of the implementation of the EMA guideline on missing data in confirmatory clinical trials: specification of mixed models for longitudinal data in study protocols. Pharm Stat. 2019;18:636&#x2013;644. doi: 10.1002/pst.1964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pst.1964</ArticleId><ArticleId IdType="pmc">PMC6899721</ArticleId><ArticleId IdType="pubmed">31267673</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagin DS. Analyzing developmental trajectories: a semi-parametric, group-based approach. Psychol Methods. 1999;4:139&#x2013;157. doi: 10.1037/1082-989X.4.2.139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/1082-989X.4.2.139</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones BL, Nagin DS, Roeder K. A SAS procedure based on mixture models for estimating developmental trajectories. Sociol Methods Res. 2001;29:374&#x2013;393. doi: 10.1177/0049124101029003005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0049124101029003005</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86:38&#x2013;44. doi: 10.1136/jnnp-2013-306589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-306589</ArticleId><ArticleId IdType="pubmed">24336810</ArticleId></ArticleIdList></Reference><Reference><Citation>Gidal BE, Ferry J, Majid O, Hussein Z. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia. 2013;54:1490&#x2013;1497. doi: 10.1111/epi.12240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/epi.12240</ArticleId><ArticleId IdType="pubmed">23772853</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH, Jr, Johnson H, Qureshi M, et al. Northeast ALS Consortium. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003;61:456&#x2013;464. doi: 10.1212/wnl.61.4.456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.61.4.456</ArticleId><ArticleId IdType="pubmed">12939417</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, et al. Ceftriaxone Study Investigators. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:1083&#x2013;1091. doi: 10.1016/S1474-4422(14)70222-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70222-4</ArticleId><ArticleId IdType="pmc">PMC4216315</ArticleId><ArticleId IdType="pubmed">25297012</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai MC, Tzeng RC, Huang CW, Wu SN. The novel direct modulatory effects of perampanel, an antagonist of AMPA receptors, on voltage-gated sodium and M-type potassium currents. Biomolecules. 2019;9:638. doi: 10.3390/biom9100638.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom9100638</ArticleId><ArticleId IdType="pmc">PMC6843791</ArticleId><ArticleId IdType="pubmed">31652643</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JE, Choi HC, Song HK, Kang TC. Perampanel affects up-stream regulatory signaling pathways of GluA1 phosphorylation in normal and epileptic rats. Front Cell Neurosci. 2019;13:80. doi: 10.3389/fncel.2019.00080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00080</ArticleId><ArticleId IdType="pmc">PMC6405474</ArticleId><ArticleId IdType="pubmed">30881292</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54:1481&#x2013;1489. doi: 10.1111/epi.12212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/epi.12212</ArticleId><ArticleId IdType="pubmed">23663001</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>